CLB
Core Laboratories N.V. NYSE$13.78
Mkt Cap $634.5M
52w Low $9.72
38.2% of range
52w High $20.36
50d MA $16.61
200d MA $15.11
P/E (TTM)
20.7x
EV/EBITDA
14.6x
P/B
2.3x
Debt/Equity
0.7x
ROE
11.2%
P/FCF
33.0x
RSI (14)
—
ATR (14)
—
Beta
1.16
50d MA
$16.61
200d MA
$15.11
Avg Volume
394.4K
About
Core Laboratories N.V. provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock, reservoir fluid, and gas samples to enhance pr…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29, 2026 | AMC | 0.06 | 0.06 | +0.0% | 17.30 | -6.8% | -15.3% | -18.7% | -20.3% | — | — | — |
| Feb 4, 2026 | AMC | 0.19 | 0.21 | +9.8% | 19.61 | -3.1% | -4.2% | -5.4% | -3.2% | -4.9% | -3.4% | — |
| Oct 22, 2025 | AMC | 0.19 | 0.22 | +15.8% | 12.77 | +18.0% | +28.8% | +32.0% | +32.0% | +29.0% | +26.2% | — |
| Jul 23, 2025 | AMC | 0.18 | 0.19 | +5.6% | 12.62 | +4.9% | +5.9% | -7.1% | -5.3% | -8.2% | -11.7% | — |
| Apr 23, 2025 | AMC | 0.15 | 0.14 | -6.7% | 12.07 | +3.6% | -3.8% | -1.7% | -6.4% | -2.9% | -5.8% | — |
| Jan 29, 2025 | AMC | 0.23 | 0.22 | -4.3% | 18.54 | -6.4% | -4.3% | -8.5% | -10.7% | -7.0% | -3.8% | — |
| Oct 23, 2024 | AMC | 0.23 | 0.25 | +8.7% | 17.08 | +4.4% | +10.9% | +13.8% | +12.3% | +14.2% | +12.9% | — |
| Jul 24, 2024 | AMC | 0.21 | 0.22 | +4.8% | 22.02 | +0.0% | +10.6% | +9.8% | +7.8% | +11.2% | +11.2% | — |
| Apr 24, 2024 | AMC | 0.16 | 0.19 | +18.8% | 16.53 | +7.9% | +3.3% | +2.5% | +2.5% | -4.4% | -5.0% | — |
| Jan 31, 2024 | AMC | 0.20 | 0.19 | -5.0% | 15.77 | +6.0% | -4.7% | -6.0% | -5.4% | -5.3% | -7.4% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 16 | Stifel | Maintains | Hold → Hold | — | $11.68 | $11.47 | -1.8% | -3.1% | -0.3% | -2.4% | -2.2% | +0.8% |
| May 13 | Citigroup | Maintains | Neutral → Neutral | — | $12.06 | $12.03 | -0.2% | +3.3% | +1.0% | -1.6% | -1.7% | -3.7% |
| Apr 15 | Stifel | Maintains | Hold → Hold | — | $12.15 | $12.08 | -0.6% | -1.3% | +1.4% | +3.9% | +0.9% | +2.4% |
| Mar 12 | Citigroup | Upgrade | Sell → Neutral | — | $14.62 | $15.04 | +2.9% | +3.1% | +0.5% | +4.2% | +1.8% | +3.9% |
| Feb 20 | Citigroup | Maintains | Sell → Sell | — | $16.88 | $16.73 | -0.9% | -0.1% | -4.4% | -5.7% | -7.6% | -11.1% |
| Oct 31 | Citigroup | Maintains | Sell → Sell | — | $19.28 | $19.05 | -1.2% | -2.0% | -2.0% | +0.2% | +1.3% | +12.1% |
| May 1 | Piper Sandler | Maintains | Neutral → Neutral | — | $22.51 | $22.13 | -1.7% | -2.1% | -5.4% | -1.3% | -4.7% | -2.8% |
| Apr 28 | Stifel | Maintains | Hold → Hold | — | $22.56 | $22.79 | +1.0% | -0.2% | -2.3% | -5.6% | -1.6% | -4.9% |
| Apr 18 | BofA Securities | Downgrade | Neutral → Underperform | — | $22.31 | $20.83 | -6.6% | -1.4% | -2.0% | -3.5% | -4.6% | -1.4% |
| Feb 7 | Citigroup | Maintains | Neutral → Neutral | — | $25.67 | $26.11 | +1.7% | +2.8% | +2.7% | -0.3% | +0.9% | +1.0% |
Recent Filings
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Core Labs is assessing Middle East geopolitical risks' impact on Q1 2026 earnings, suggesting potential revenue disruption from reduced oil demand or operational challenges that could pressure stock performance.
Mar 23
8-K
Unknown — 8-K Filing
Colibri Group discovered tax accounting adjustments during 10-K preparation that may impact reported earnings and cash tax obligations, requiring investor attention to the full magnitude when disclosed.
Mar 17
8-K · 5.03
! Medium
Core Laboratories Inc. -- 8-K 5.03: Amendment to Articles / Bylaws
Core Laboratories changed its fiscal year end, which may affect investor reporting schedules and comparability with prior periods, though the operational impact is likely minimal.
Mar 5
NT 10-K
!!! Very High
Core Laboratories Inc. -- Late Annual Report -- Distress Signal
Core Laboratories requested an extension to file its annual report due to complex multi-jurisdictional tax accounting issues, signaling potential delays in financial statement completion and possible material tax liabilities.
Mar 3
8-K · 7.01
! Medium
Core Laboratories Inc. -- 8-K 7.01: Regulation FD Disclosure
Core Laboratories will distribute $0.01 per share dividend to shareholders on March 9, 2026, maintaining its modest quarterly payout to investors.
Feb 4
Data updated apr 25, 2026 1:33am
· Source: massive.com